Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > oh dear

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Jun 05, 2023 10:25am

124 Views

Post# 35480279

RE:RE:RE:RE:oh dear

Azzak34 - KOL presentation... and compelling new data... yet ONCY pps is down again.

Please explain what I am missing...? What is it the market seems to dislike about this company ? Is it perhaps 24 years of missed timelines, non statisically powered data, unclear signals of efficacy, prior failed Phase III trial, ?

Clinical Trial partners who have exclusive access to the data and walk away...

does none of this concern you..? or are you perfectly happy with how this company is being run, the decisions made, and then results thus far presented..?

well, I suppose we only have until 2028 to get this approved, before any old tom can make it... maybe you azzak, maybe even you..

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"